ArticleCancer research communications2025

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.

Peng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.